MyOme's predictive genomic insights that support proactive healthcare run on Oracle Cloud Infrastructure

MENLO PARK, Calif., Sept. 24, 2026 /PRNewswire/ -- MyOme, Inc., a leader in clinical whole-genome analysis and polygenic risk modeling, today announced that its predictive genomic insights platform and testing services that run on Oracle Cloud Infrastructure (OCI) are now available worldwide. MyOme is combining its genomics capabilities with OCI's global scale and security to help shift healthcare from reactive treatment toward proactive health management. In addition, MyOme has joined Oracle PartnerNetwork (OPN) to help bring its capabilities to more healthcare organizations through the Oracle ecosystem and the Oracle Marketplace.

"Our collaboration with Oracle is an important step toward making predictive genomics available at global scale," said Matt Rabinowitz, PhD, executive chairman of MyOme. "Pairing MyOme's whole-genome platform with OCI's global infrastructure lets us identify people at high risk for preventable disease early enough to act on it."

MyOme sequences each individual's whole genome once, then uses OCI's high-performance and low latency computing to analyze millions of genetic variants alongside clinical risk factors. It evaluates each individual's risk for rare and common diseases and uses AI-driven population-scale models to produce integrated polygenic risk scores for common conditions (including coronary artery disease, type 2 diabetes, prostate cancer, and breast cancer) alongside monogenic findings and pharmacogenomic guidance. Unlike most genetic testing that reads a narrow gene panel and reports a handful of high-penetrance variants, MyOme's approach uses a whole-genome backbone. As a result, one sample produces broad clinical insights and the same data can be re-queried as a patient's health evolves and science advances.

MyOme's rollout is supported by OCI's global scale and security. Running on OCI will help MyOme expand access to predictive genomic insights and make risk information available early enough to support more timely decisions and interventions.

"By making predictive genomics accessible, clinicians have more information to decide on the right intervention at the right time," said Dan Spellman, group vice president, AI and OCI, Healthcare & Life Sciences, Oracle. "Together, we're driving toward a better standard for healthcare globally."

About MyOme

MyOme is a clinical whole genome analysis company helping families understand their risk for diseases. As a leader in polygenic and AI-based integrative risk modeling, MyOme's platform combines genome sequencing with AI-driven analytics to integrate polygenic risk scores with established clinical predictors, enabling a more comprehensive approach to disease risk assessment. MyOme leverages the power of the whole-genome and clinical data for a lifetime of clinically meaningful and actionable insights. These capabilities can dramatically reduce healthcare costs and improve outcomes by identifying disease risk earlier and enabling preventive interventions. Certified under the Clinical Laboratory Improvement Amendments (CLIA) and accredited by the College of American Pathologists (CAP), MyOme is based in Menlo Park, California.

SOURCE MyOme, Inc

Share this article

Nework Unveils New Smart Living Tools for More Organized, Intentional Everyday Life

- As smart calendars and inkless boards emerge as the next essential home productivity tools, Nework introduces NewFlow and NewSlate, alongside storewide October Prime deals.

POMONA, Calif., Sept. 24, 2026 /PRNewswire/ -- In recent years, a quiet shift has been happening in modern homes and hybrid workspaces. As life gets busier, consumers are moving away from traditional distraction-heavy screens and paper clutter, actively seeking tools that bring calm, structure, and intention to their daily lives. Among these emerging lifestyle tech trends, two products are fast becoming must-haves: smart digital calendars that bring family schedules into focus, and inkless writing boards that offer a clean, friction-free canvas for instant ideas.

People no longer just want more technology—they want tools that seamlessly blend into their environment. Smart digital calendars give families a centralized hub to sync schedules and track chores, while inkless writing boards offer a sustainable, marker-free space to map out thoughts without paper waste.

Meeting this shift in consumer demand, audiovisual and collaborative solutions provider Nework is officially expanding its smart living portfolio this October with two brand-new releases: NewFlow (Smart Digital Calendar) and NewSlate (Inkless Writing board).

NewFlow: The Ultimate Central Hub for the Modern Home

Designed to streamline busy household logistics, NewFlow brings agendas, tasks, and routines together into one sleek, ambient display.

- Seamless Syncing: Automatically integrates with Google Calendar, iCloud, and Outlook.

- Family-Centric Planning: Features color-coded member profiles, interactive chore lists, meal planners, and shared grocery lists.

- Remote Access: Adjust schedules on the go via the companion mobile app.

- Ambient Photo Mode: When not in planning mode, NewFlow doubles as an elegant digital photo frame that blends naturally into modern home decor.

NewSlate: A Cleaner, Distraction-Free Canvas for Ideas

Built for quick brainstorming, study workflows, and daily reminders, NewSlate provides a natural, pen-on-paper writing feel without the clutter of sticky notes or traditional dry-erase markers.

- Natural Writing Experience: Low-latency response ensures smooth, precise strokes and effortless partial or full erasing.

- Sustainable & Efficient: An eco-friendly, energy-efficient design that eliminates paper waste and marker ink disposal.

- Focused Workspace: Keeps quick notes visible without adding another notification-heavy screen to your environment.

October Savings Across Nework's Flagship Lines

Alongside the new product introductions, Nework will participate in Amazon's Prime Big Deal Days with a limited-time 48-hour promotion from October 6 to October 7.

The promotion includes 15%-20% off the NewBoard Smart Board Series and more than 20% off the MoveMate Portable TV Series, providing early holiday shoppers with savings across Nework's existing work and entertainment portfolio.

As consumers look to upgrade their home technology or get an early start on holiday shopping, the promotion offers savings on products designed around increasingly flexible ways of working, relaxing, and spending time at home.

The NewBoard Series is designed to support collaboration and productivity in home offices and shared spaces, bringing communication, content, and everyday workflows together on one interactive display. For entertainment, the MoveMate Series offers a more flexible viewing experience, allowing users to bring their screen to different spaces around the home rather than organizing their routines around a fixed TV setup.

Through its upcoming launches and October deals, Nework continues to focus on technology that simplifies daily tasks and integrates work, home, and personal time seamlessly.

About Nework

Nework is an innovative brand specializing in audiovisual presentation and collaborative products, headquartered in California, USA. Its portfolio includes interactive displays, portable TVs, cameras, speakerphones, and accessories. Its solutions are available across two specialized platforms: Nework.ai for professional smart boards and workplace collaboration; Nework.us for portable lifestyle TVs and more smart home devices.

With its mission of empowering users through advanced audiovisual, interactive, and AI technologies, Nework aims to improve presentation, collaboration, and communication while making everyday experiences more seamless and enjoyable.

For more information, please visit https://www.nework.ai/ or connect with Nework:

Facebook: https://www.facebook.com/neworkai

Instagram: https://www.instagram.com/nework.us/

LinkedIn: https://www.linkedin.com/company/nework-ai

YouTube: https://www.youtube.com/@Nework-ai

SOURCE NEWORK LLC

Share this article

Two-Year Grant Cycle Supports Nonprofits Dedicated to Serving Arizona Communities

PHOENIX, Sept. 24, 2026 /PRNewswire/ -- Desert Financial Credit Union has awarded $260,000 in grants to 21 Arizona nonprofits this year as part of its 2026 grant program. The funding marks the first year of a two-year grant cycle totaling $520,000 in support of organizations making an impact in communities across Arizona.

Since 2013, Desert Financial has provided nearly $2.6 million in grant support to Arizona nonprofits.

Among this year's recipients is Tynkertopia, which was awarded $10,000 to support 300 youth and young adults through its Future Ready: STEAM, Workforce & Financial Pathways program. The program combines workforce readiness, entrepreneurship and financial literacy with STEAM education at Tynkertopia MakerSpace, the nonprofit's new hands-on learning facility.

"Research shows that investing in STEAM education equips young people with the skills, confidence and experiences they need to succeed in tomorrow's workforce," said Jack Biggs, executive vice president at Desert Financial. "When we support teens and young adults on their journey toward career readiness, we're building a stronger future for all of Arizona."

The two-year structure is designed to give nonprofit partners greater stability and more time to focus on serving their communities. Organizations that fulfill the grant requirements during the first year will not need to reapply to receive the same funding in 2027.

"For the past five years, Desert Financial Credit Union has been an invaluable partner in helping Tynkertopia expand opportunities for children, teens and families in northern Arizona," said Dr. Alice Christie, CEO of Tynkertopia. "We are grateful for their confidence in our mission and are honored to continue building the partnership as we prepare Arizona's next generation for college, careers, financial wellbeing and lifelong success."

The 2026 grant recipients include:

- A New Leaf Inc. — $15,000: Providing financial education and workforce readiness skills for resident teens and youth.

- Billy's Place, Inc. — $12,500: School-based grief support in Maricopa County.

- Boys & Girls Club of Central Arizona — $10,000: Career readiness and outdoor adventure programs for teens in Prescott and Prescott Valley.

- Boys & Girls Clubs of Greater Scottsdale — $15,000: Workforce readiness programming for teens in Scottsdale.

- Boys & Girls Clubs of the Valley — $15,000: Life and workforce readiness programs for underserved youth in Phoenix and surrounding communities.

- Catholic Charities Community Services, Inc. — $7,500: Financial literacy education for refugees.

- Children's Museum of Phoenix — $10,000: Free or reduced-price STEM field trips and books for children in need in Phoenix.

- Earn to Learn — $15,000: Matched-savings scholarship programming in Maricopa County and rural Arizona.

- Future for Kids — $12,500: Youth mentorship programs in Phoenix, Tempe and Mesa.

- Jobs for Arizona's Graduates — $15,000: Career and college readiness programs.

- Laptops 4 Learning — $15,000: Laptops for students in the Phoenix area.

- Literacy Volunteers of Coconino County — $7,500: Reading support for kindergarten and first-grade students in Flagstaff.

- Lowell Observatory — $12,500: STEAM education for fourth- through eighth-grade students on the Navajo, Hopi and Apache nations.

- Native American Connections — $12,500: After-school and summer programming in Phoenix.

- Save the Family Foundation of Arizona — $10,000: Children's services aimed at helping families overcome homelessness in the East Valley.

- Society of St. Vincent de Paul — $15,000: Workforce Opportunities programming in Phoenix.

- Southwest Autism Research & Resource Center — $15,000: Inclusive preschool programming for children with autism in Phoenix, Tempe and Scottsdale.

- Southwest Human Development — $15,000: Early childhood education and family support in Phoenix.

- The Launch Pad Teen Center — $12,500: Workforce development programming for young adults ages 16 to 24 in Prescott.

- Tynkertopia — $10,000: Workforce readiness and financial education for teens and young adults in Flagstaff.

- Yavapai Big Brothers Big Sisters — $7,500: Expansion of youth services throughout Yavapai County.

For more information about Desert Financial and its grant program, visit https://www.desertfinancial.com/en/who-we-are/community-involvement/how-we-give-back

About Desert Financial Credit Union

For more than 87 years, Desert Financial has been Arizona's most trusted local credit union with more than 500,000 members and $9 billion in assets. With 50+ locations across Arizona and top-rated digital banking, it's easy for members to click, call or come in. In 2026, members received $16 million back via the Member Giveback Bonus. Desert Financial is the official retail banking partner of Arizona State University® and the official banking partner of the Arizona Cardinals, NAU Athletics and the NAU Alumni Association. Federally insured by NCUA. Learn more at DesertFinancial.com.  

SOURCE Desert Financial Credit Union

Share this article

OVERLAND PARK, Kan., Sept. 24, 2026 /PRNewswire/ -- Aria Care Partners has named Veda Lewis-Simmons, DPM, MHA to the position of chief medical officer of podiatry. The role is responsible for operational effectiveness and clinical quality of the company's onsite podiatry services for skilled nursing facilities (SNF).

Dr. Lewis-Simmons earned both a master's degree in healthcare administration and a Doctor of Podiatric Medicine and Surgery from Des Moines University Medicine and Health Sciences. She completed her residency at University of Texas Health Science Center in San Antonio and is board certified.

In addition to operating her own mobile foot care practice, Dr. Lewis-Simmons became the owner and executive director of Attentive Adult Day Center in Missouri in 2018. Previously, she served as associate medical director at U.S. Medical Management (now HarmonyCares), a home-based care organization, where she supervised medical staff, helped develop clinical guidelines, and strengthened community relations. Dr. Lewis-Simmons also spent many years building and leading successful surgical private podiatry practices throughout Missouri.

"Dr. Lewis-Simmons brings extensive clinical expertise and proven healthcare leadership that make her uniquely suited for this role," said John Griscavage, CEO of Aria Care Partners. "Her experience and vision will be instrumental in advancing our podiatry program, supporting our clinical teams and further enhancing care for the residents we serve."

Added Dr. Lewis-Simmons, "I am excited to join Aria Care Partners and share the company's commitment to delivering compassionate, high-quality care in skilled nursing communities," said Dr. Lewis-Simmons. "I look forward to partnering with our clinical teams to advance the podiatry program, support exceptional resident care and build on the strong foundation."

About Aria Care Partners

Aria Care Partners is a leading provider of integrated onsite ancillary care and insurance solutions for skilled nursing facilities. With more than 25 years of experience and partnerships with over 3,500 skilled nursing facilities nationwide, Aria delivers coordinated dental, vision, hearing, and podiatry services through a comprehensive care delivery model designed to improve access, streamline operations, and support better resident outcomes. By aligning clinical services, coverage, and care coordination through a single partner, Aria Care Partners helps facilities reduce complexity while enhancing residents' quality of life and providing peace of mind for their families. For more information, please visit www.ariacarepartners.com.

Media Contact:

Allison Murphy, Director of Marketing Operations

(913) 594-3088

[email protected]

SOURCE Aria Care Partners

Share this article

ACROBiosystems Introduces CHO-Direct and ACRO AIx to Accelerate AI-driven Drug Discovery

SAN DIEGO, Sept. 24, 2026 /PRNewswire/ -- Recently, ACROBiosystems unveiled its latest innovation portfolio—ACRO AIx, CHO-Direct and GlobalLifeShip cross border supply chain to respond the demand of AIDD era.

As artificial intelligence becomes increasingly integrated into drug discovery, the design and screening of candidate molecules are becoming more efficient. Experimental validation is emerging as a critical link between computational predictions and R&D decisions. In AI-driven Drug Discovery (AIDD), rapidly generating candidate sequences is only the starting point. Obtaining reliable, reproducible experimental data in a timely manner—and using those data to assess function and development potential—is essential to advancing research programs.

To address this need, ACROBiosystems is introducing the CHO-Direct Rapid High-Throughput Affinity Validation Service and ACRO AIx, expanding its portfolio of products and experimental validation capabilities for AI-driven drug discovery. CHO-Direct provides a rapid entry point for candidate validation, delivering affinity data for antibodies in as little as four days from sequence submission. ACRO AIx brings together standardized products, reproducible validation modules, and experimental tools to build wet-lab infrastructure for AI-enabled research across the industry. As one of its core applications, CHO-Direct connects with R&D workflows through open interfaces.

CHO-Direct Provides a Four-Day Fast-Track Entry Point to an End-to-End AIDD Validation Workflow

In AI-driven antibody discovery, computational approaches can rapidly generate large numbers of candidate sequences, while downstream expression and testing often struggle to keep pace, limiting the efficiency of candidate screening and model iteration. To address these challenges, ACROBiosystems is launching the CHO-Direct Rapid High-Throughput Affinity Validation Service. Using an optimized CHO cell system and an efficient workflow, the service delivers affinity data for antibodies in as little as four days from sequence submission. It draws on the protein-folding and post-translational modification environment of mammalian cells and maintains continuity with CHO systems commonly used in downstream development and manufacturing, creating a rapid, digital validation workflow from sequence input to structured data output.

For pharmaceutical companies, biotechnology companies, and AIDD research teams, CHO-Direct offers more than faster access to affinity data. It provides a consistent experimental pathway for evaluating computational predictions. Standardized validation enables candidates to undergo experimental assessment earlier, helping teams focus their R&D resources on candidates that warrant further investigation.

Rapid validation is the entry point. ACROBiosystems has established a portfolio of products and tools covering more than 5,000 target proteins and over 300 challenging membrane protein targets. The company is also expanding its high-throughput TR-FRET kits for functional pathway inhibition screening and reporter cell lines available for commercial licensing worldwide. These capabilities extend into cellular function and higher-order models, supporting a multidimensional, multilevel AIDD validation platform spanning proteins, cells, and organoids.

Validation can then extend to cellular and higher-order models. Using overexpression, knockout, and reporter cell lines, researchers can assess cell binding, internalization, immune activation, and pathway modulation to investigate candidate function and mechanism of action. Human 3D organoid models derived from human induced pluripotent stem cells (hiPSCs), including heart, brain, skin, and kidney models, can support efficacy, dose-response, and related functional assessments, providing early experimental data with greater biological relevance. Results across these levels complement one another, providing a more comprehensive experimental basis for continued candidate optimization and advancement decisions.

ACRO AIx Builds Wet-Lab Infrastructure for Biopharmaceutical Research in the AI for Science Era

Building on the rapid validation capabilities provided by CHO-Direct, ACRO AIx addresses broader needs for experimental reproducibility, data connectivity, and workflow coordination in AI-enabled R&D. CHO-Direct is a directly accessible, standardized validation service within this infrastructure. ACRO AIx encompasses a wider range of products, tools, and multilevel validation capabilities, allowing research teams to choose how to engage according to their laboratory resources and project stage.

In addition to using the CHO-Direct service, customers can adopt the CHO-Direct Tool Set, comprising high-expression CHO cell lines, dedicated culture media, and transfection reagents, to reproduce the expression system in their own laboratories. For VHHs, small proteins, and early-stage high-throughput exploration, ACROBiosystems plans to introduce the CFS Tool Kit, using cell-free expression to support more flexible experimental needs. Tools such as ExpSolPredictor and SeqOptimizer bring experimental insights upstream into sequence design. Drawing on accumulated expression data, they predict soluble expression performance and inform sequence optimization related to expression yield, stability, and aggregation risk.

Connecting products and data is another integral component of ACRO AIx. The AIDD-Ready protein library provides researchers with in-stock target proteins, tools for challenging membrane protein targets, and custom development support for new target proteins. Planned open APIs will connect inventory and lead-time information, structured product parameters, lot-specific quality reports, and order fulfillment status, enabling AI tools and R&D workflows to access relevant product and data capabilities. Together with a tiered validation framework spanning proteins, cells, and organoids, ACROBiosystems AIx aims to create more seamless connections between computational design, experimental execution, and data feedback.

Beyond early-stage drug discovery, ACRO AIx also extends into AI4CMC, the application of AI to pharmaceutical development and manufacturing processes. To address efficiency, reliability, and cost needs in biologics manufacturing, ACROBiosystems is developing a portfolio of key materials, including cytokines, enzymes that tolerate specific process conditions, AI protein-enhanced culture media, and novel affinity ligands. The company has already begun working with selected partners to advance AI-designed proteins toward larger-scale industrial applications.

ACRO AIx is positioned as open infrastructure serving the industry. ACROBiosystems provides products, tools, validation, and fulfillment capabilities. It does not develop its own drug pipeline or undertake complete, end-to-end R&D projects; customers retain their molecules, intellectual property, and associated data. This approach enables the company to support the needs of different research teams and help customers integrate experimental capabilities into their own R&D operations.

GlobalLifeShip cross border supply chain serving global market

ACROBiosystems is also introducing the GlobalLifeShip cross border supply chain. The platform's capabilities include cross-border transportation, overseas warehousing, and last-mile delivery available to partners. Drawing on ACROBiosystems' supply chain and global hubs built through serving life science customers worldwide, the platform supports partners in entering and serving international markets, complementing the company's research products and experimental validation capabilities.

About ACROBiosystems

ACROBiosystems Group, founded in 2010 and listed in 2021, is a biotechnology company aimed at being a cornerstone of the global biopharmaceutical and healthcare industries by providing innovative products and business models. The company spans across the globe and maintains offices, R&D centers, and production bases in more than 15 different cities within the United States, Switzerland, the United Kingdom and Germany. ACROBiosystems Group has established numerous long-term and stable partnerships with the world's top pharmaceutical enterprises, including Pfizer, Novartis, and Johnson & Johnson, and numerous well-known academic institutes. The company comprises several subsidiaries such as ACROBiosystems, bioSeedin, Condense Capital, and ACRODiagnostics.

ACROBiosystems' brands include Resilient Supply, CytoPak, SAFENSURE, FLAG, Star Staining, Aneuro, ComboX, GENPower and many others. Its main products and services are recombinant proteins, kits, antibodies, scientific services, and other related products. ACROBiosystems employs a strict quality control system for its products that are used in biopharmaceutical research and development, production, and clinical application. This includes targeted discovery and validation, candidate drug screening/optimization, CMC development and pilot production, preclinical research, clinical trials, commercial production, and clinical application of companion diagnostics.

Through the continuous development of new technologies and products, ACROBiosystems Group creates value for the global pharmaceutical industry and actively empowers our partners. The company is dedicated to accelerating the drug development process, including targeted therapies, immunotherapeutic drugs, and their clinical applications, and contributes to global health.

SOURCE ACROBiosystems

Share this article

SAN FRANCISCO, Sept. 24, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP—a national plaintiffs' rights law firm with a premier securities practice group—notifies investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) of the upcoming September 28, 2026 lead plaintiff deadline in the ongoing securities class action. This alert follows the U.S. Food and Drug Administration's (FDA) recent decision to extend the review period for Capricor's Biologics License Application (BLA), underscoring the ongoing regulatory and disclosure scrutiny surrounding the company.

Hagens Berman encourages investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) who suffered substantial losses to submit your losses now.

FDA Extends BLA Review Following Post-AdCom Submissions

On Aug. 24, Capricor announced that the FDA has extended the Prescription Drug User Fee Act (PDUFA) target action date for Capricor's lead investigational cell therapy, deramiocel, for the treatment of Duchenne muscular dystrophy (DMD), moving the decision date from August 22, 2026, to November 22, 2026.

The agency classified Capricor's recent submission—which follows a turbulent July 2026 Advisory Committee meeting and includes 24-month open-label extension data from the Phase 3 HOPE-3 study alongside a request to pivot toward a refined indication focused solely on upper limb function—as a major amendment.

Securities Class Action Details & Overview

- Class Period: Dec. 17, 2025 – July 26, 2026

- Lead Plaintiff Deadline: Sept. 28, 2026

- Visit: www.hbsslaw.com/capr

- Contact the Firm Now: [email protected] / 844-916-0895

View our latest video summary of the allegations: youtu.be/-lnVTKgV6as

Core Allegations and Background

- Material Misleading Statements Regarding Clinical Trial Data and SAP Changes: The lawsuit alleges that Capricor and certain executives made materially false and misleading statements regarding the clinical trial data and regulatory pathway for its lead product candidate, Deramiocel, intended to treat Duchenne muscular dystrophy (DMD). Specifically, defendants allegedly failed to disclose that they adopted changes to the pre-specified statistical analysis plan (SAP) without agreement from the U.S. Food and Drug Administration (FDA) prior to resubmitting its Biologics License Application (BLA).

- The HOPE-3 Trial Breakthrough and Subsequent Capital Raise: On December 3, 2025 Capricor announced "Positive Topline Results from Pivotal Phase 3 HOPE-3 Study of Deramiocel in Duchenne Muscular Dystrophy." The company's CEO said "HOPE-3 delivered strong and definitive evidence that Deramiocel can meaningfully improve the course of Duchenne muscular dystrophy, demonstrating statistically significant improvements in both skeletal and cardiac function." Driven by these claims, Capricor's share price surged 370% to close up $23.60 on December 3, 2025. The following day, the company launched a public stock offering of approximately 6 million shares priced at $25 per share.

- FDA Briefing Document Reveals SAP Changes and Triggers 64% Stock Collapse: Capricor's public assurances unraveled on July 27, 2026, when the FDA published briefing documents ahead of an Advisory Committee meeting. The documents revealed that Capricor made unagreed-upon post-hoc modifications to its pre-specified Statistical Analysis Plan (SAP). The FDA stated that the HOPE-3 study "did not meet its pre-specified primary and secondary efficacy endpoints showing no statistically significant difference between deramiocel and placebo at 12 months." Capricor shares crashed roughly 64% in a single day to close at $7.00. An Advisory Committee subsequently voted 9–3 against the efficacy of the drug, compounding investor losses.

Hagens Berman's Investigation

"We're focused on investors' losses and uncovering the full scope of how management characterized these trial endpoints and undisclosed modification," said Reed Kathrein, the Hagens Berman partner leading the firm's investigation on the claims alleged in the pending suit.

What Affected CAPR Investors Should Do

If you purchased or acquired Capricor securities between December 17, 2025, and July 26, 2026, and suffered significant financial losses, you have until September 28, 2026, to ask the court to appoint you as lead plaintiff. You do not need to seek lead plaintiff status to share in any potential recovery.

To learn more about your legal options, submit your information to Hagens Berman, visit www.hbsslaw.com/capr, call Reed Kathrein at 844-916-0895, or email [email protected].

If you'd like more information and answers to frequently asked questions about the Capricor case and the firm's investigation, read more »

Whistleblowers: Persons with non-public information regarding Capricor should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman

Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. 

Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.

SOURCE Hagens Berman Sobol Shapiro LLP

Share this article

SAN FRANCISCO, Sept. 24, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in Pentair plc (NYSE: PNR) that a securities fraud class action lawsuit filed against the company has been expanded to cover an earlier class period. Investors who suffered substantial losses are urged to submit their losses now.

CASE DETAILS

Expanded Class Period: March 11, 2025 – July 14, 2026 (Previously April 28, 2026 – July 14, 2026)

Lead Plaintiff Deadline: Oct. 2, 2026

Contact Hagens Berman: Visit www.hbsslaw.com/pnr, email [email protected], or call (844) 916-0895

ALLEGED MISCONDUCT & EXPANDED CLASS PERIOD

The new class action lawsuit alleges that beginning on March 11, 2025, Pentair plc and certain of its top executives made a series of materially false and misleading statements and omitted critical adverse operational information regarding Pentair's financial health, channel inventory, and internal controls.

Specifically, the lawsuit alleges Defendants failed to disclose that:

- Pentair was experiencing severe, undisclosed channel inventory destocking—particularly within its core Pool segment.

- The company engaged in unsustainable channel-loading and sales practices with distributors to artificially inflate short-term financial metrics.

- As a result, Pentair's positive statements regarding its business, full-year financial guidance, and operating income lacked a reasonable basis.

THE DISCLOSURE & MARKET REACTION

The complaint alleges that the artificial inflation in Pentair shares came to an abrupt end on July 14, 2026, after the market closed, when Pentair shocked investors by pre-announcing preliminary second-quarter 2026 financial results that fell substantially below consensus estimates.

The disclosures revealed severe operational headwinds:

- Massive Revenue Miss: Sales were expected to be approximately $930 million—a drastic miss against prior forecasts of $1.14 billion. The company disclosed that inventory destocking in the Pool channel negatively impacted Pool segment sales by approximately $170 million and income by approximately $105 million.

- Full-Year Guidance Slashed: Pentair dramatically cut its full-year 2026 outlook, reversing earlier projections. Full-year sales were projected to be down approximately 4% to 7%, compared to prior guidance of up 2% to 4% growth.

- Abrupt CFO Departure: Compounding the shock, Pentair announced the immediate departure of its Chief Financial Officer, Nicholas Brazis, after serving in the role for only four months, raising questions regarding internal controls and financial reporting.

Following these disclosures, Pentair's stock price plummeted 15% in a single session—losing $11.35 per share to close at $64.33 on unusually heavy trading volume on July 15, 2026.

"We are closely examining the timing of these disclosures, the sudden departure of the CFO after only four months, and the severe impact of channel destocking on Pentair's financial health," said Reed Kathrein, the Hagens Berman partner leading the firm's investigation of the alleged claims.

What Affected PNR Investors Should Do

If you purchased or acquired Pentair common stock between March 11, 2025, and July 14, 2026, and suffered significant financial losses, you have until October 2, 2026, to ask the court to appoint you as lead plaintiff.

To learn more about your legal options, submit your information to Hagens Berman, visit www.hbsslaw.com/pnr, call Reed Kathrein at 844-916-0895, or email [email protected].

If you'd like more information and answers to other frequently asked questions about the Pentair case and the firm's investigation, read more »

Whistleblowers: Persons with non-public information regarding Pentair should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman

Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. 

Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.

SOURCE Hagens Berman Sobol Shapiro LLP

Share this article

A securities class action alleges AppLovin overstated the reliability of the "virtuous cycle" and "compounding" value proposition behind its AI advertising models, and APP shareholders lost $82.13 per share when the Company reported a revenue miss.

NEW YORK, Sept. 24, 2026 /PRNewswire/ -- SueWallSt alerts investors in AppLovin Corporation (NASDAQ: APP) of a pending securities class action on behalf of shareholders who purchased securities between February 12, 2026 and August 5, 2026. Check if you might be eligible to recover your investment losses. You may also contact Joseph E. Levi, Esq. at [email protected] or (888) SueWallSt.

APP closed at $335.67 on August 6, 2026, down $82.13 per share, or 19.66%, after the Company reported second quarter revenue of $1.92 billion against consensus estimates of $1.94 billion. The Court has set November 16, 2026 as the deadline to apply for lead plaintiff appointment.

"Investors deserve transparency about material risks that could affect their investments. Here, the action claims AppLovin described a self-reinforcing 'virtuous cycle' in which better AI models pulled in more advertiser budget, without disclosing that the pace of meaningful model improvement was allegedly already running lighter than normal." -- Joseph E. Levi, Esq.

The Alleged "Virtuous Cycle" Compounding Claims

The lawsuit asserts that management told investors AppLovin's advertising business ran on a self-reinforcing loop: engineers improved the AI models, advertisers earned better returns on ad spend, budgets stepped up, and the additional data made the models better still. Management described that loop to investors as "a virtuous cycle, and it is working," as alleged. Earlier in the Class Period, the Company framed a 20% to 30% growth opportunity as attainable through "directed model enhancements and recursive learning" that was "happening on an ongoing basis."

AI Advertising Trends Behind the Compounding Thesis

- Performance advertising platforms compete primarily on model quality, because higher measured returns pull incremental budget from advertisers.

- The compounding thesis assumes every new advertiser contributes engagement and transaction data that sharpens the models, which then attracts more advertisers.

- Model gains originate in internal research and A/B testing, and the action claims investors were not told those gains arrive unevenly rather than on a dependable quarterly cadence.

- When a compounding step-up is absent in a given quarter, revenue growth can decelerate faster than prior commentary implied.

- The action claims the benefits and reliability of the compounding value proposition were overstated, both to advertiser customers and to shareholders.

Why "Compounding" Reliability Allegedly Matters to Investors

Growth presented as structurally self-reinforcing is priced differently than growth that depends on research outcomes in any three-month window. The lawsuit asserts that shareholders who bought during the Class Period paid prices reflecting a dependable compounding engine, and were harmed when the Company's disclosures corrected that premise.

Learn more about the case or call (888) SueWallSt.

WHY SUEWALLST: SueWallSt is powered by Levi & Korsinsky LLP. Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.

Frequently Asked Questions About the APP Lawsuit

Q: What is the APP lead plaintiff deadline? A: The deadline to apply for lead plaintiff appointment is November 16, 2026. This deadline applies only to investors seeking to serve as lead plaintiff. Class members who do not apply may still participate in any recovery without taking action before this date.

Q: How much did APP stock drop? A: Shares fell approximately 19.66%, a decline of $82.13 per share, after the Company disclosed second quarter revenue of $1.92 billion that missed consensus estimates and acknowledged that its pace of meaningful AI model improvement had slowed while its generative AI video creative tool remained in progress. Investors who purchased shares during the Class Period at artificially inflated prices and suffered losses may be eligible to seek compensation.

Q: What specific misstatements does the APP lawsuit allege? A: The complaint alleges AppLovin made materially false or misleading statements regarding the constancy and reliability of improvements to its AI models, the overstated "virtuous cycle" and "compounding" value proposition of those models, and the development status of its generative AI video creative tool during the Class Period. When the slower pace of model improvement and the unfinished video tool were disclosed, the stock price declined sharply.

Q: What is a lead plaintiff and why does it matter? A: A lead plaintiff is the investor appointed by the court to represent the entire class. Lead plaintiffs are typically investors with the largest documented losses. Being appointed does not increase individual recovery but gives direct oversight of how the case is run.

Q: What documents do I need to submit my information? A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.

Q: What if I already sold my APP shares, can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought during the Class Period and sold at a loss may still be eligible to participate.

Q: Do I need to go to court or give testimony? A: No. The overwhelming majority of class members never appear in court or give depositions. If there is a settlement or recovery, eligible class members generally submit a claim form to seek their portion.

Q: What does it cost me to participate? A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in the securities class action, they are generally handled on a contingency basis, with any attorneys' fees and expenses subject to court approval.

CONTACT:\

Levi & Korsinsky, LLP\

Joseph E. Levi, Esq.\

33 Whitehall Street, 27th Floor\

New York, NY 10004\

Tel: (888) SueWallSt\

Fax: (212) 363-7171

Attorney Advertising. Prior results do not guarantee similar outcomes.

SOURCE SueWallSt.com

Share this article

New Research Finds Nearly 40% of Known Relevant Threats Lack Coverage as Agentic Cyberwarfare Raises the Stakes

Conifers' analysis of 14,652 detections finds nearly half of deployed detections don't work as intended, and the problem extends far beyond the SIEM into every layer of the security stack

DALLAS and TEL AVIV, Israel, Sept. 24, 2026 /PRNewswire/ -- Conifers, developer of the CognitiveSOC™ agentic AI SOC platform, today released The Detection Blind Spot, a new research report based on an analysis of 14,652 detections in live enterprise environments. The security industry has treated detection volume, including rules deployed and tools onboarded, as a measure for detection strength. Conifers' research suggests that assumption is masking a much larger problem.

Detection gaps are not new but the speed and scale at which agentic adversaries can find and exploit them is. That makes reliable, continuously validated detections more important than ever, yet many detection programs still rely on manual tuning, periodic reviews, or, too often, no review at all.

Across the environments studied, organizations had working detections, hunts or compensating visibility for only 63% of the threats they had identified as relevant. More than a third of the threats organizations already know are coming at them have no corresponding operational coverage to defend against them. Coverage extended to only 64% of the MITRE ATT&CK® techniques relevant to each environment. The findings reveal an operationalization gap between the threats organizations know matter and the working detections in place to find them.

The research also found that 47% of detections required attention before they could be trusted to work as intended. Yet these detections could still appear as deployed or healthy in traditional inventory-based reporting.

The issues fell into five primary categories, including logic issues that prevented detections from firing correctly; missing telemetry caused by data sources that stopped flowing or were never onboarded; queries pointed at the wrong data tables; duplicate detections that increased alert volume without improving coverage; and noisy detections that fired so frequently or imprecisely that analysts learned to ignore them.

Efforts to validate detection quality have traditionally focused on the SIEM because those rules are directly visible and editable by security teams. But SIEM rules represent only one source of the detections entering the SOC queue. Endpoint, cloud, identity, email, and network security products each generate their own vendor-authored detections. When a vendor-owned detection is noisy or ineffective, security teams often cannot fix the underlying logic. They are left to suppress it, accept the blind spot, or allow the noise to continue until analysts begin tuning it out.

"The underlying problem with threat detection isn't that detections were poorly written. It's that the telemetry beneath them changes, making detections stale and ineffective without anyone realizing it. That creates a real blind spot," said Rutger de Boer, CTO at DTX. "Conifers' research validates what we see with our customers every day: continuous detection validation is becoming a foundational function of the modern SOC. By continuously testing detections at scale, organizations gain confidence in their security posture while significantly reducing the manual effort required from analysts, improving both effectiveness and operational efficiency."

"For years, the industry has measured detection strength by counting rules and tools. But deployed is not the same as protected," said Tom Findling, CEO and co-founder of Conifers. "As agentic adversaries compress the time defenders have to adapt, security teams need to know which detections work, which threats remain uncovered, and how quickly intelligence becomes protection. That requires threat intelligence, exposure data, hunting, and detection engineering to operate as one continuous system, not as siloed functions connected by tickets and quarterly reviews."

The report outlines six actions security leaders can take to close the gap: measure coverage through verified working detections mapped to the threats and techniques relevant to the organization, rather than raw detection counts; extend detection health management beyond the SIEM to include vendor-managed detections that security teams cannot directly edit; establish a control point that tunes, deduplicates, and suppresses detections across tools before they reach the analyst queue; track intelligence operationalization, including the time between identifying a relevant threat and deploying a verified working detection; anchor threat hunting in exposure data and the organization's crown-jewel assets; and feed relevant, validated hunt findings back into detection engineering to improve coverage.

The full report, The Detection Blind Spot, is available at: https://www.conifers.ai/white-papers/the-detection-blind-spot/.

About Conifers

Conifers builds CognitiveSOC™, the agentic AI SOC platform that powers Resilient Cyber Defense. It connects threat intelligence, threat hunting, detection engineering, investigation, and remediation as one adaptive system on top of the security tools organizations already own. Organizations use CognitiveSOC to evolve their existing security operations into a continuously adapting operating layer capable of keeping pace with the frontier model era. Learn more at conifers.ai.

Learn more at www.conifers.ai.

Media Contact:

Rachel Glaser

White City PR for Conifers [email protected]

SOURCE Conifers Inc

Share this article

Drone measurements by Aspen Snowmass show 85% of snow volume remained under the insulated mats through the Colorado summer.

SANTA FE, N.M., Sept. 24, 2026 /PRNewswire/ -- Snow Secure's insulated mats have passed their first Colorado summer in a snow storage pilot project at Aspen.

Snow was covered at Aspen Snowmass in April, with Snow Secure's continuous temperature monitoring running from April 30 through August 31.

Drone measurements by Aspen management on August 31 showed 85% of the snow volume remaining under the mats. The measurements include both summer melt and the natural compression of the stored snow.

24/7 monitoring at Snowmass shows the conditions the insulation faced. Over the period, the temperature sensor on top of the mats averaged 61.8°F (16,5°C) and peaked at 118°F (47,8°C) in the Colorado summer sun.

Directly beneath the insulation, at the snow surface, the temperature averaged just 33.6°F (0,9°C).

"Resorts cannot control the autumn weather, but snow storage gives them another way to control when they have snow available. Insulation is what makes summer storage possible in demanding conditions. Effective insulation, combined with an integrated rain cover, keeps the snow protected through the summer," said Antti Lauslahti, CEO of Snow Secure.

Aspen Snowmass describes the pilot:

"As part of our industry-leading commitment to sustainability and climate resilience, Aspen Snowmass is piloting Snow Secure blanket technology at Buttermilk and Snowmass — Colorado's first deployment of this proven European system. By covering existing snowpack through summer, we can reduce our reliance on early-season snowmaking, conserving water and energy while delivering a better guest experience from opening day. We'll monitor results throughout summer to inform how we scale this technology across our mountains in the future."

Snow Secure is scaling rapidly in North America, where more than ten ski resorts have adopted the patented system in two seasons. Worldwide, Snow Secure has completed more than 150 installations, and its insulated mat technology was named one of TIME's Best Inventions of 2025.

Snow Secure provides patented snow-storage systems for ski resorts. Combining Finnish engineering with practical mountain-operations expertise, the company provides snow storage validation, planning and larger-scale master planning for ski resorts. In North America, Snow Secure works with SMI Snow Makers as its distribution partner for new ski resort projects.

SOURCE Snow Secure USA Inc

Share this article